14th Asian and Oceanic Society of Regional Anaesthesia and Pain  Medicine

CALL FOR ABSTRACT SUBMISSION

All scientific abstracts are considered for:

  • Moderated session presentation
  • Exhibit hall presentation
  • Inclusion in all meeting guide and

Deadlines and Overview

  • Abstract Submission Deadline (no extensions): July 15, 2017,  at 5 pm Eastern
  • Abstract Notifications Sent: July 31, 2017
  • Early-Bird Registration Cut-Off: May  31, 2017
  • ePoster Submission Deadline: August 15, 2017
  • Pre-Registration Deadline for Inclusion in Meeting Materials: August 31, 2017

Download  the  complete  call  for  abstracts. Abstracts must be submitted in PDF via the online submission system at www.aosra-pm.com. Abstracts

must be formally submitted before the deadline in order to be considered. 
Key abstract submission guidelines include:

  • In proper and grammatically correct English
  • No limit to the number of abstracts that may be submitted
  • If previously submitted to a different meeting an abstract may still be submitted
  • The submitting author is required to ensure that all co-authors are aware of the abstract content before submission
  • AOSRA-PM does not share with an institution or employer information of those who have submitted abstract(s)
  • A presenter is expected to attend the meeting and present the poster
  • Meeting registration is required at least 6 weeks prior to the meeting in order to be included in the final program
  • There is no fee to submit an abstract, but there is a $30 fee to submit an ePoster after abstract acceptance
  • Quality suitable for publication and strict adherence with all requirements outlined in the call for abstracts

Abstract Category

  • Scientific Abstracts
  • Acute Pain
  • Chronic Pain
  • Regional Anesthesia
  • Emerging Technology
  • Education
  • Case Series (5 or more patients)
  • Medically Challenging Cases (report of up to 4 cases having a similar presentation; case series of 5 or more patients must be presented as a scientific abstract)

Abstract Title

The Abstract Title must be limited to 20 words in sentence format.

Submitting  Author Details

The submitting author will receive all communications regarding the abstract and is responsible for informing the other authors, as necessary.

Co-Author(s) Details

Name, contact information, role (author, co-author, presenting author), and display/list order.

Abstract Body

Strictly limited to 500 words over the following content areas:

  • Introduction
  • Material and Methods (NA for case reports)
  • Results / Case Report
  • Discussion
  • References (max. 5 references, not included in 500 word count)
  • Tables (not included in 500 word count)
  • Maximum 3 tables of 10 rows x 10 columns
  • Images (not included in 500 word count)
  • Patient faces must be entirely covered
  • Only figures in JPG format may be uploaded
  • Maximum 2 images
  • Maximum file size of each image is 500 KB
  • Maximum pixel size is 600(w) x 800(h) pixel

Important Considerations

  • No promotional content of a commercial entity may be included (brand/trade/product names, photos, logos, company names, ).
  • If necessary for clarity, a trade/product name may be included parenthetically once in the materials and methods section, but no more, and not in the abstract title. If more than one company makes the product, all applicable trade names are identified.
  • Any off-label indications should be clearly marked as such.

Conflicts of Interest Disclosure

All submissions require disclosure of financial or other relationships with a commercial interest producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients.

Disclosure must include the company name(s) and nature of relationship (honoraria/expenses, consulting/ advisory board, funded research, royalties/patent, stock options, equity position/ownership, employee, other similar relations). Disclosure is required for the submitting author and their spouse/partner over the last 12 months.

Patient and/or Institutional Review Board (IRB) Approval

  • I included in the abstract text that I have obtained patient and/or institutional review board (IRB) approval

Off-Label Drug Use

  • If my study involves off-label use of drugs placed near the neuraxis, I have obtained an FDA IND and/or I have followed the conditions set forth regarding such experimentation.
  • If my study involves off-label use of drugs for peripheral nerve block, I have obtained IRB approval.
  • Any off-label indications have been clearly marked as such.
  • There are no off-label indications
  • Trade Names
  • No promotional content of a commercial entity is included (brand/trade/product names, photos, logos, company names, etc.).
  • If necessary for clarity, a trade/product name is included parenthetically once in the materials and methods section, but no more, and not in the abstract title. If more than one company makes the product, all applicable trade names are identified.
  • Copyrighted Material
  • There are no copyrighted figures, images, or content in my abstract.
  • If copyrighted figures, images or content are contained in my abstract, I have obtained the necessary permission from the copyright owner.
  • Other
  • All patient protected health information has been de-identified; patient faces are entirely covered.
  • I would like my abstract to be considered for oral presentation during the moderated poster sessions.

Agreement and Submission

  • I reviewed this abstract and all information is correct. I accept that the content of this abstract cannot be modified or corrected after final submission; I am aware that it will be published exactly as submitted.
  • I and all others listed as (co-)authors contributed substantively to the writing, review, and work described by this abstract, and further affirm that it was not prepared or written by anyone not listed as an author
  • I am the sole owner and/or have the rights of all the information and content. The publication of the abstract does not infringe any third party rights including, but not limited to, intellectual property I herewith grant AOSRA-PM a royalty-free, perpetual, irrevocable nonexclusive license to use, reproduce, publish, translate, distribute, and display the abstract content.
  • Submission of the abstract constitutes my consent to print and/or electronic publication (e.g. meeting website, program, other promotions, )
  • The submitting author is responsible for informing the other authors about the status of the abstract.
  • I understand that my abstract may be immediately rejected and/or removed from any publication if it does not thoroughly comply with all of the above requirements.

Review and Grading Process

Abstracts are blind reviewed by at minimum 2 committee members and are graded using a 3 to 1 scale, with 3 being “must accept and consider for best of  meeting”,  2  being  “accept”  and  one  1  being “reject” (reason for rejection to be briefly stated). The AOSRA-PM committee performing the review and selecting abstracts for presentation is identified based on the abstract  category.

Scientific Abstracts

  • Research Committee
  • Support from the Scientific/Education Committee members with expertise in each field as necessary

Medically Challenging Cases

  • Scientific/Education Planning Committee The AOSRA-PM committee review and ranking of abstract submissions does not constitute peer review and should not be interpreted as such. Notification regarding the status (accepted for poster presentation or rejected) will be sent to the abstract author approximately 2 months prior to the meeting. Some submitted abstracts may not be accepted based on their quality or space limitations at the meeting venue.

Reviewer Checklist

Reviewers will complete the checklist below to verify that all requirements are integrated into the submitted abstract. Abstracts not complying with all requirements will be automatically rejected. There will be no revision and resubmission period or process.

Submission  Requirements:

  • The abstract is correctly
  • The abstract is incorrectly categorized and should be re-categorized (see comments).
  • All abstract content areas are thoroughly completed.
  • Conflicts of interest disclosure and financial support have been declared
  • IRB, animal use committee, and/or patient consent stated or waived, as necessary
  • If off-label use, proper approval obtained (IND and/or IRB) and/or follows conditions set forth regarding such experimentation
  • Any off-label indications have been clearly marked as such
  • No promotional content has been used (brand/ trade names, logos, ultrasound logos, etc.). If necessary for clarity, a trade/product name is included parenthetically once in the Materials and Methods section, but no more, and not in the abstract title. If more than one company makes the product, all applicable trade names are identified
  • Copyright permission obtained, if Scoring:
  • 3: Accept and consider for oral presentation and best of meeting
  • 2: Accept
  • 1: Reject
  • Comments, reasons for rejection, or re- categorization: (open text box)
  • Incorrectly categorized; Recategorize to Scientific Abstract
  • Incorrectly categorized; Recategorize to Medically Challenging Case

ePoster Fee

AOSRA-PM does not charge a fee to submit an  abstract.  However,  $30  will  be  charged  for  each abstract actually accepted for ePoster presentation. This payment is non-refundable and partially offsets AOSRA-PM’s cost for abstract presentation in the ePoster format. This ePoster fee is generally less expensive  than printing a poster; printed posters are not accepted. The ePoster fee will be charged after abstract acceptance and upon online submission of the ePoster (ePoster Submission Deadline: August 15, 2017).

Meeting Pre-Registration

Only abstracts/ePosters by authors who register no later than the ePoster submission deadline will be included in the final program and meeting materials. Meeting registration is refundable according to the meeting  cancellation policy.

Eligibility

Only authors listed on the submitted abstract may present onsite during the meeting. Investigators who have abstracts approved for presentation but fail to attend the meeting three years in a row will be prohibited from submitting abstracts for the following two years.

ePoster Display

All abstracts accepted for poster presentation during the meeting will be available onsite each day using ePoster technology. Multiple plasma screens will be available in a clearly identified viewing area. Authorswill have 10-15 minutes for scheduled presentation, grouped by category and subcategory as much as possible. The ePosters will not be formally moderated during  general  viewing hours.

Moderated ePoster Sessions

Upon submission, authors will have the option to indicate if they would like to be considered for oral presentation during the meeting. The maximum number of moderated sessions will be determined by the project management team based on program organization and meeting space; AOSRA-PM will provide as many opportunities as possible. Moderated poster sessions will include at least one dedicated session for medically challenging cases. All other sessions will be allocated for presentation of scientific abstracts; these sessions will be structured according to category and subcategory as much as possible. The final number of presentations will be based on the quality of submitted abstracts. Posters will be moderated at various times by various moderators. 9 to 12 abstracts will be assigned per session. Each presenter will be allocated maximum 10 minutes per poster (5 minutes presentation and 5 minutes discussion).

 

Resident/Fellow Best of Meeting Abstracts (Scientific Abstracts only)

The top 10 highest scoring scientific abstracts that have met all AOSRA-PM abstract submission requirements will be sent to the research committee, which will select 3 best of meeting abstracts.

Best of abstract winners benefit  from  the following.

  • Inclusion in a moderated poster session
  • Certificate of achievement (mailed by the AOSRA-PM office after the meeting)
  • Poster is tagged in the ePoster system.Best of meeting award recipients must be present to receive the award and participate in the above presentation activities.  If a winner is  unable to participate, an alternative award winner will be selected. Best of meeting award recipients must be present to receive the award and participate in the above presentation activities.  If a winner is  unable to participate, an alternative award winner will be selected.

AOSRA-PM Society and/or Meeting Websites

Abstracts (as submitted for initial grading) will be included on the AOSRA-PM website for three years (starting from 2017). All submitted ePosters will be available online prior to the meeting. Medically challenging cases ePosters are removed three months after the meeting and scientific abstracts after maximum three years.

For Inquiries: PSA Secretariat: Philippine Society of Anesthesiologists Inc. Suite 102 PMA Building, North Avenue, Diliman 1100, Manila, Philippines
Email: aosra_pm2017@yahoo.com | Telefax: (632)9295852 Mobile: +(63)917 832 9069; +(63) 920 952 2120

© 2017 AOSRA-PM All Rights Reserved. Designed by: Word Scientific Communications Int'l. Inc.